Teriparatide
Sold as Forteo, Increscotyde, Tericresco, Sondelbay, Teratyde, Ostepar
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 5
- Registrations
- 6
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Eli Lilly (S.A.) (Pty) LtdCertificate held by Eli Lilly (S.A.) (Pty) Limited | Forteo | 250 µg/ml | 360334 | S4 | PIPIL |
| Cipla Medpro (Pty) Ltd | Increscotyde, Tericresco | Not stated | 560877, 560878.877 | S4 | None |
| Accord Healthcare (Pty) Ltd | Sondelbay | Not stated | 570474 | S4 | None |
| Ranbaxy Pharmaceutical (Pty) Ltd | Teratyde | Not stated | 580003 | S4 | None |
| Trinity Pharma (Pty) Ltd | Ostepar | 250 μg/ml | 590885 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Forteo EACH 1,0 ml SOLUTION CONTAINS TERIPARATIDE 250,0 ug | 250 µg/mlSolution for injection | 36033436/21.4/0334Approved 17 March 2022 | Registered | S4 | PIPIL |
| Increscotyde EACH 1,0 ml SOLUTION CONTAINS TERIPARATIDE 250,0 µg | Not listed | 56087756/21.4/0877 | Registered | S4 | None |
| Tericresco EACH 1,0 ml SOLUTION CONTAINS TERIPARATIDE 250,0 µg | Not listed | 560878.877 | Registered | S4 | None |
| Sondelbay EACH 1,0 ml SOLUTION CONTAINS: TERIPARATIDE 250,0 μg | Not listed | 57047457/21.4/0474 | Registered | S4 | None |
| Teratyde Each 1,0 ml Solution contains: Teriparatide 250,0 μg | Not listed | 58000358/21.4/0003 | Registered | S4 | None |
| Ostepar 250 μg/ml EACH 1,0 ml SOLUTION CONTAINS: TERIPARATIDE 250,0 μg | 250 μg/ml | 59088559/21.4/0885 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Teriparatide
S4: Teriparatide
Consolidated Schedules 06 July 2026, line 8146
Pharmacological class: Parathyroid preparations. (class 21.4)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.